Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to assess efficacy and safety of 3 doses of
apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional
treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the
treatment of subjects with acute symptomatic deep-vein thrombosis.